328.51
2.17 (0.66%)
| Previous Close | 326.34 |
| Open | 329.39 |
| Volume | 103,813 |
| Avg. Volume (3M) | 190,639 |
| Market Cap | 9,182,446,592 |
| Price / Earnings (Forward) | 30.12 |
| Price / Sales | 3.76 |
| Price / Book | 1.28 |
| 52 Weeks Range | |
| Earnings Date | 13 Feb 2025 - 17 Feb 2025 |
| Profit Margin | -30.18% |
| Operating Margin (TTM) | 9.94% |
| Diluted EPS (TTM) | -28.09 |
| Quarterly Revenue Growth (YOY) | 2.80% |
| Quarterly Earnings Growth (YOY) | 514.70% |
| Total Debt/Equity (MRQ) | 18.54% |
| Current Ratio (MRQ) | 6.14 |
| Operating Cash Flow (TTM) | 412.00 M |
| Levered Free Cash Flow (TTM) | 91.24 M |
| Return on Assets (TTM) | 1.86% |
| Return on Equity (TTM) | -9.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Bio-Rad Laboratories, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 2.38 |
|
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Core |
| % Held by Insiders | 15.57% |
| % Held by Institutions | 87.67% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 481.00 (RBC Capital, 46.42%) | Buy |
| Median | 465.50 (41.70%) | |
| Low | 450.00 (Citigroup, 36.98%) | Buy |
| Average | 465.50 (41.70%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 351.90 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 09 Dec 2024 | 481.00 (46.42%) | Buy | 345.60 |
| 31 Oct 2024 | 469.00 (42.77%) | Buy | 358.19 | |
| Citigroup | 31 Oct 2024 | 450.00 (36.98%) | Buy | 358.19 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 08 Jan 2025 | Announcement | Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests |
| 02 Jan 2025 | Announcement | Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference |
| 21 Nov 2024 | Announcement | Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference |
| 31 Oct 2024 | Announcement | Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference |
| 30 Oct 2024 | Announcement | Bio-Rad Reports Third-Quarter 2024 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |